QUAVONLIMAB
UNII GG0AN49Y59

Substance Identification & Data

This profile provides standardized clinical and technical data for Quavonlimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GG0AN49Y59.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2254059-25-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

GG0AN49Y59

CAS Registry Number

2254059-25-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

QUAVONLIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C150679

National Cancer Institute reference terminology for clinical and research data.

INN ID

11234

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-70

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Quavonlimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

QUAVONLIMAB

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4) (HUMAN-MUS MUSCULUS MONOCLONAL M3 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL M3 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), HUMANIZED MONOCLONAL ANTIBODY

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HUMANIZED (1-445) (VH (HOMO SAPIENS IGHV3-72*01 (84.7%)-(IGHD)-IGHJ4*01 (92.9%)) CDR-IMGT (8.10.6) (26-33.51-60.99-104) (1-115)-HOMO SAPIENS IGHG1*01 (100%) G1M17,1 (CH1 K120 (212) (116-213), HINGE 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)), (224-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-6*01 (81.6%)-IGKJ2*02 (90.9%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (224-224'':227-227'')-BISDISULFIDE; PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA

QUAVONLIMAB [INN]

QUAVONLIMAB [USAN]

QUAVONLIMAB [WHO-DD]